https://clinicaltrials.gov/ct2/show/NCT04451772?type=Intr&cond=Lupus&phase=012345&lupd_s=06%2F16%2F2020&lupd_d=14
Condition : Systemic Lupus Erythematosus (SLE)
Interventions : Drug: Elsubrutinib; Drug: Placebo for Elsubrutinib; Drug: Upadacitinib; Drug: Placebo for Upadacitinib
Sponsor : AbbVie
Not yet recruiting
A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State
NCT04451772
Tue, 30 Jun 2020 12:00:00 EDT
